MARKET

INNT

INNT

INNOVATE BIOPHARMACEUTICALS INC
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.7303
+0.0051
+0.70%
Closed 16:00 12/10 EST
OPEN
0.7170
PREV CLOSE
0.7252
HIGH
0.7500
LOW
0.7170
VOLUME
60.20K
TURNOVER
--
52 WEEK HIGH
4.320
52 WEEK LOW
0.7100
MARKET CAP
1.88M
P/E (TTM)
-1.0954
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of INNT and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

INNT News

  • The Daily Biotech Pulse: Patent Win For Cellectis, Hepion Proves Efficacy In Animal Model, Job Cuts At Neon
  • Benzinga.11/21 12:22
  • How a merger could mean the 'next Salix' for Raleigh
  • American City Business Journals.11/18 17:32
  • RDD Pharma Enters into Non-Binding Letter of Intent to Acquire Naia Rare Diseases, Strengthening Gastroenterology Orphan Disease Pipeline
  • PR Newswire.11/13 13:00
  • Triangle drugmaker plans merger with Israeli pharma -- what it means for Raleigh
  • American City Business Journals.10/07 19:38

More

Industry

Biotechnology & Medical Research
+0.51%
Pharmaceuticals & Medical Research
-0.29%

Hot Stocks

Name
Price
%Change

About INNT

Innovate Biopharmaceuticals, Inc., formerly Monster Digital, Inc., is a clinical stage biotechnology company. The Company is focused on developing novel autoimmune and inflammation therapeutic drugs. Its lead drug candidate, larazotide acetate (INN-202) is a tight junction regulator. Its other products include INN-108 and INN-329 (Secretin). The Company’s INN-108 is a novel small molecule comprised of two active parts with anti- inflammatory and immunodulatory properties coupled through an azo bond. The Company is developing INN-108 as a therapeutic for Ulcerative Colitis (UC). Its Secretin stimulated magnetic resonance cholangiopancreatography (MRCP) is a ionizing, radiation-free assessment of the pancreaticobiliary system. The Company has completed a phase II b clinical trial for celiac disease for INN-202. It is developing INN-108 in a phase II trial for inflammatory bowel disorders, mild to moderate UC and a Gastrointestinal (GI) orphan disease.
More

Webull offers Innovate Biopharmaceuticals Inc (INNT) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.